NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing